Core Viewpoint - The company has issued a positive profit forecast, expecting a net profit exceeding RMB 240 million in 2025, representing a year-on-year growth of approximately 139.4%, with revenue anticipated to exceed RMB 1.05 billion, a year-on-year increase of about 34.6% [1][2]. Performance Overview - The company is set to release its audited annual report soon, likely before March 2026, following the positive earnings announcement [2]. Business Development - In January 2026, the company announced a strategic acquisition of the German company Optimed to accelerate its penetration into the European market. By the end of 2025, its sales channels had expanded to cover 83 countries, with overseas revenue growing by over 100% year-on-year. Future focus will be on the synergies from the acquisition, overseas regulatory approvals, and progress in new market expansions [3]. Product Development - The sales performance of products such as the Qianqiao Qilin blood flow guiding device and ZYLOX Swan venous catheter was strong in 2025. Additionally, innovative products like the carotid double-layer mesh stent have entered the "green channel" of the National Medical Products Administration. The approval of new products and the volume of existing products in a centralized procurement environment may become market focal points [4]. Stock Performance - Following the positive earnings forecast and internationalization progress, the company's stock price rose nearly 7% on February 3, 2026, with a trading volume of HKD 17.88 million. If the official earnings report exceeds expectations or new developments in strategic layout emerge, it may further influence short-term market sentiment [5].

Core Viewpoint - Guichuang Tongqiao (02190) has announced a positive earnings forecast, expecting a significant increase in net profit and revenue for 2025, driven by strong sales of core products and accelerated international business growth [1] Financial Performance - The company anticipates a net profit exceeding RMB 240 million for 2025, representing a substantial year-on-year increase of approximately 139.4% [1] - Projected operating revenue is expected to surpass RMB 1.05 billion, reflecting a year-on-year growth of about 34.6% [1] Product Sales Growth - Sales revenue from key products such as the Tongqiao Qilin blood flow guiding device, neurovascular guide wire, UltraFree drug-eluting PTA balloon catheter, and ZYLOX Swan venous RF closure catheter have all experienced rapid growth [1] International Business Expansion - The company's international sales revenue has more than doubled year-on-year, with significant market penetration in key countries such as Germany, France, and Italy [1] - The internationalization strategy has achieved critical breakthroughs, leading to a comprehensive acceleration in overseas market expansion [1]

Core Viewpoint - Guichuang Tongqiao (02190) has announced a positive earnings forecast, expecting a significant increase in net profit and revenue for 2025, driven by strong sales of core products and international market expansion [1] Financial Performance - The company anticipates a net profit exceeding RMB 240 million for 2025, representing a substantial year-on-year growth of approximately 139.4% [1] - Projected operating revenue is expected to exceed RMB 1.05 billion, reflecting a year-on-year increase of about 34.6% [1] Product Performance - Sales revenue from key products such as the Tongqiao Qilin blood flow guiding device, neurovascular guidewire, UltraFree drug-eluting PTA balloon catheter, and ZYLOX Swan venous RF closure catheter have all experienced rapid growth [1] International Expansion - The company's international sales revenue has more than doubled year-on-year, with significant market penetration in key countries such as Germany, France, and Italy [1] - The internationalization strategy has achieved critical breakthroughs, accelerating the expansion into overseas markets [1]

Core Viewpoint - Guichuang Tongqiao (02190) has issued a positive profit forecast for the year 2025, expecting a significant increase in net profit and revenue compared to the previous year [1] Group 1: Financial Performance - The company anticipates a net profit exceeding RMB 240 million for 2025, representing a substantial year-on-year growth of approximately 139.4% [1] - Revenue is expected to surpass RMB 1.05 billion, reflecting a year-on-year increase of about 34.6% [1] Group 2: Product Performance - Sales of core products such as the Qilin blood flow guiding device, neurovascular guide wire, UltraFree drug-eluting PTA balloon catheter, and ZYLOX Swan intravascular radiofrequency closure catheter have all experienced rapid growth [1] Group 3: International Expansion - The company has achieved a significant breakthrough in its international strategy, with sales channels covering 83 countries and regions globally and over 80 strategic partnerships established with overseas partners [2] - By the end of 2025, the company plans to further expand its presence in Europe and the global market through the strategic acquisition of the German company Optimed [2] - The collaboration between production bases in China and Germany is expected to enhance global operational and delivery capabilities [2]

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. expects a significant increase in its 2025 financial performance, with net profit projected to exceed RMB 240 million, representing a year-on-year growth of approximately 139.4%, and revenue anticipated to surpass RMB 1.05 billion, reflecting a year-on-year increase of about 34.6% [1][2] Group 1: Financial Performance - The company forecasts a net profit exceeding RMB 240 million for 2025, marking a substantial increase of around 139.4% compared to the previous year [1] - Expected revenue for 2025 is over RMB 1.05 billion, which indicates a year-on-year growth of approximately 34.6% [1] Group 2: Product and Market Development - The strong financial performance is attributed to robust sales growth of core products, accelerated development of overseas business, and continuous optimization of operational efficiency [1] - Key products such as the Tongqiao Qilin blood flow guiding device, neurovascular guide wire, UltraFree drug-eluting PTA balloon dilation catheter, and ZYLOX Swan venous intraluminal radiofrequency closure catheter have all seen rapid sales growth [1] - International sales revenue has more than doubled year-on-year, with increasing market penetration in key countries like Germany, France, and Italy [1] Group 3: Strategic Initiatives - The company is focusing on "innovation" and "internationalization" as core strategies to drive business layout and upgrades [2] - Several innovative products have been approved for market launch, including the ZYLOX Mammoth large lumen peripheral thrombectomy catheter and Tongqiao Feilong intracranial aneurysm embolization assist stent, which have shown positive market performance [2] - The company has expanded its sales channels to cover 83 countries and regions globally and established strategic partnerships with over 80 overseas partners [2] - A strategic acquisition of the German company Optimed was announced to enhance the company's presence in the European and global markets [2]